Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment
2024 · Advanced Materials
저자
Sangjun Moon, Mungyo Jung, Seokhyeong Go, Jihye Hong, Hee Su Sohn, Cheesue Kim, Mikyung Kang, Byung Joon Lee, Jung-Woo Kim, Jinwoong Lim, 김병수 (Byung‐Soo Kim)
연구주제
Cancer Immunotherapy and Biomarkers · Immune cells in cancer · Nanoplatforms for cancer theranostics
NTIS 과학기술표준분류
가장 가까운 분류(생명과학 > 융합바이오 > 나노바이오소재)가 화학·화공 범위 밖이다. 배정 근거: 논문을 지원한 과제의 분류.
AI 연구 키워드·방법
dual immune checkpoint inhibition engineered nanoparticle t cell activation tumor associated macrophage
키워드 (OpenAlex)
engineered nanoparticles tumor-associated macrophages T cell activation dual immune checkpoint inhibition CD47 PD-L1 PD-1 phagocytosis
초록
T cells and macrophages have the potential to collaborate to eliminate tumor cells efficiently. Macrophages can eliminate tumor cells through phagocytosis and subsequently activate T cells by presenting tumor antigens. The activated T cells, in turn, can kill tumor cells and redirect tumor-associated macrophages toward an antitumoral M1 phenotype. However, checkpoint molecules expressed on tumor cells impede the collaborative action of these immune cells. Meanwhile, monotherapy with a single immune checkpoint inhibitor (ICI) for either macrophages or T cells yields suboptimal efficacy in cancer patients. To address this challenge, here a nanoparticle capable of efficiently delivering dual ICIs to tumors for both macrophages and T cells is developed. These programmed cell death protein 1 (PD-1)-transfected macrophage membrane-derived nanoparticles (PMMNPs) can target tumors and provide si…
이 논문을 지원한 국가R&D 과제 (NTIS 성과)
| 연도 | 과제 | 부처 | 사업 | 수행기관 | NTIS 분류(1순위) |
|---|---|---|---|---|---|
| 2024 | 알츠하이머병 치료를 위한 항체치료제의 혈관-뇌 장벽(BBB) 투과율 향상 및 2가지 병인을 동시 타겟하는 항체-약물 접합체(ADC) 개발 | 과학기술정보통신부 | 개인기초연구(과기정통부) | 서울대학 | 범위 밖 |
인접 그래프
노드 hover = 이웃 강조 · 1회 클릭 = 고정 · 고정된 노드 다시 클릭 = 페이지 이동
이 문서와 연결된 페이지
교수 1
연구주제 1
Cancer Immunotherapy and Biomarkers